Key facts
- This page summarizes David M. Chao's Form 4 filing for Centessa Pharmaceuticals plc (CNTA).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Mar 2025, 16:47.
David M. Chao - 17 Mar 2025 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)
- Reporting relationship
- Chief Administrative Officer
- Issuer ticker
- CNTA
- Reported as of
- 17 Mar 2025
- Net transaction value
- -$106,731
- SEC form
- 4
- Accepted by SEC
- 19 Mar 2025, 16:47:53 UTC
- Prior SEC filing
- 04 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gregory Weinhoff, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David M. Chao filed Form 4 for Centessa Pharmaceuticals plc (CNTA) on 19 Mar 2025.
Change
- Previous filing in this sequence was filed on 04 Feb 2025.
- Current net transaction value: -$106,731.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNTA
transaction
Ordinary Shares
Options Exercise
- Transaction value
- $13,475
- Shares
- +3,500
- Change %
- +1.5%
- Price
- $3.85
- Shares after
- 232,007
- Date
- 17 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
CNTA
transaction
Ordinary Shares
Sale
- Transaction value
- $93,576
- Shares
- -5,478
- Change %
- -2.4%
- Price
- $17.08
- Shares after
- 226,529
- Date
- 17 Mar 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
CNTA
transaction
Ordinary Shares
Sale
- Transaction value
- $26,630
- Shares
- -1,522
- Change %
- -0.67%
- Price
- $17.50
- Shares after
- 225,007
- Date
- 17 Mar 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNTA
transaction
Derivative
Share Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -3,500
- Change %
- -3%
- Price
- $0.000000
- Shares after
- 111,500
- Date
- 17 Mar 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 3,500
- Exercise price
- $3.85
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2024.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.45 to $17.445, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.455 to $17.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F5
1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023.